Published in Psychopharmacology (Berl) on January 25, 2005
A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med (2002) 5.65
The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic (1985) 4.59
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry (2005) 2.39
Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. Am J Ment Retard (2001) 2.23
Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry (2001) 2.06
Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry (2002) 1.89
Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics (2002) 1.87
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry (2002) 1.60
Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry (1997) 1.54
The prevalence of challenging behaviors: a total population study. Res Dev Disabil (2001) 1.44
Early conduct problems and later life opportunities. J Child Psychol Psychiatry (1998) 1.44
Are there any successful men from criminogenic backgrounds? Psychiatry (1988) 1.43
An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry (1998) 1.43
A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry (2000) 1.30
Neuroreceptor mechanisms of aggression and its treatment. J Clin Psychiatry (2003) 0.99
Risperidone for aggression and self-injurious behavior in adults with mental retardation. J Autism Dev Disord (1998) 0.97
Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study. Acta Psychiatr Scand (1993) 0.96
Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol (2002) 0.91
Psychopharmacotherapy in children and adults with intellectual disability. Lancet (1999) 0.86
Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol (2001) 0.86
An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull (1997) 0.81
Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. J Child Adolesc Psychopharmacol (2000) 0.80
Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry (1994) 0.79
Substituting traditional antipsychotics with risperidone for individuals with mental retardation. Ment Retard (1996) 0.79
Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism. J Autism Dev Disord (1999) 0.79
Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry (2002) 2.80
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry (2005) 2.62
Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry (2005) 2.52
Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry (2003) 2.24
Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol (2009) 1.76
Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry (2004) 1.70
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res (2007) 1.68
Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry (2003) 1.66
Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res (2009) 1.62
Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry (2009) 1.61
Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig (2010) 1.60
Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry (2007) 1.58
Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol (2007) 1.46
Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother (2010) 1.42
A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int J Stroke (2012) 1.42
A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology (2010) 1.24
Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord (2009) 1.20
Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. CMAJ (2008) 1.15
Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res (2004) 1.11
Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. CMAJ (2008) 1.08
Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol (2005) 1.06
Management of mild to moderate Alzheimer's disease and dementia. Alzheimers Dement (2007) 1.06
Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry (2004) 1.03
Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol (2004) 1.01
Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol (2008) 1.01
Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry (2008) 0.96
Creating bridges between researchers and long-term care homes to promote quality of life for residents. Qual Health Res (2010) 0.96
A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J Psychopharmacol (2009) 0.95
Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol (2005) 0.92
Stroke patients' and carers' perception of barriers to accessing stroke information. Top Stroke Rehabil (2010) 0.92
Randomised controlled trial of an education and support package for stroke patients and their carers. BMJ Open (2013) 0.90
Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. Int J Geriatr Psychiatry (2004) 0.89
The suitability of written education materials for stroke survivors and their carers. Top Stroke Rehabil (2003) 0.89
Evaluation of screening tools for dementia in older adults with mental retardation. Am J Ment Retard (2004) 0.89
Changes in white matter connectivity following therapy for anomia post stroke. Neurorehabil Neural Repair (2013) 0.88
Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol (2006) 0.87
Assessment of behavioural and psychological symptoms associated with dementia. Can J Neurol Sci (2007) 0.87
Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. Am J Geriatr Psychiatry (2006) 0.84
Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. Br J Psychiatry (2005) 0.84
A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of adjunctive carisbamate treatment in patients with partial-onset seizures. Epilepsia (2011) 0.84
Delivery styles and formats for different stroke information topics: patient and carer preferences. Patient Educ Couns (2010) 0.83
A functional MRI study of the relationship between naming treatment outcomes and resting state functional connectivity in post-stroke aphasia. Hum Brain Mapp (2014) 0.82
A comparative investigation of observational pain assessment tools for older adults with dementia. Clin J Pain (2012) 0.81
A controlled investigation of continuing pain education for long-term care staff. Pain Res Manag (2013) 0.80
One-year open-label safety and efficacy study of paliperidone extended-release tablets in patients with schizophrenia. CNS Spectr (2010) 0.80
Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol (2011) 0.80
A qualitative investigation of injurious falls in long-term care: perspectives of staff members. Disabil Rehabil (2010) 0.79
An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder. Int Clin Psychopharmacol (2006) 0.79
Use of vitamin and mineral supplements in long-term care home residents. Appl Physiol Nutr Metab (2012) 0.78
Response to "A graphic reanalysis of the NINDS Trial". Ann Emerg Med (2010) 0.78
A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy. Clin Drug Investig (2015) 0.77
Penumbral topography in human stroke: methodology and validation of the 'Penumbragram'. Neuroimage (2004) 0.75
The effect of risperidone on nursing burden associated with caring for patients with dementia. J Am Geriatr Soc (2005) 0.75
Tramadol article conclusion troubling. Pain Physician (2014) 0.75
Adverse event reporting in the recent study by Imanaka et al. describing the efficacy and safety of tapentadol extended release for tumor-related pain. Curr Med Res Opin (2014) 0.75
QEEG may uniquely inform and expedite decisions regarding intra-arterial clot retrieval in acute stroke. Clin Neurophysiol (2013) 0.75
Stroke patients' awareness of risk and readiness to change behaviors. Top Stroke Rehabil (2011) 0.75
Challenges in planning long-term care menus that meet dietary recommendations. Can J Diet Pract Res (2013) 0.75